Spontaneous Hypoglycaemia due to Insulin Autoimmune Syndrome in Six Cases, Response to Steroid Therapy and Rituximab

• Published in: Indian journal of endocrinology and metabolism 2024-05, Vol.28 (3), p.295-301
• Main Authors: Batra, Chandar M, Jain, Savita, Kumar, Kiran P, Goyal, Monika, Kachroo, Varsha, Takkar, Simran, Yadav, Rini
• Format: Article
• Language: English
• Subjects: Autoantibodies; Autoimmune diseases; autoimmune hyperinsulinism; Autoimmunity; B cells; Blood sugar; Blood sugar monitoring; Clopidogrel; Corticosteroids; Development and progression; glucocorticoids; Glucose monitoring; Health aspects; hirata disease; Hydrochlorothiazide; Hypoglycemia; Imipenem; Insulin; insulin autoantibodies; Monitoring systems; Multiple myeloma; Original; Pancreatic beta cells; Pantoprazole; Patients; Prednisolone; rituximab; spontaneous hypoglycaemia; Steroids; Tomography; Zoledronic acid
• ISSN: 2230-8210; 2230-9500
• DOI: 10.4103/ijem.ijem_378_23

Dr. Hirata of Japan first described insulin autoimmune syndrome (IAS) in 1970. Seven hundred ninety-five cases of this rare syndrome have been reported from Japan and China and 29 from India. IAS has the following characteristic features 1) severe spontaneous attacks of hyperinsulinemic hypoglycaemia, 2) high total immunoreactive insulin levels, 3) elevated insulin autoantibody (IAA) titres, 4) no prior exposure to exogenous insulin, and 5) no pathological abnormalities of the pancreatic islet cells. We treated six cases of IAS with high doses of prednisolone for 4-6 weeks and then gradually reduced the doses. Diagnosis of IAS was established by documenting Whipple's triad of symptoms and signs of hypoglycaemia, blood sugar 3 uU/ml, C-peptide levels >0.6 ng/ml, and increased titres of anti-insulin autoantibodies. Insulinoma and non-pancreatic tumours were ruled out by CECT (contrast-enhanced computerised tomography) or MRI (magnetic resonance imaging) of the abdomen and if necessary endoscopic ultrasonography and gallium 68 Dotanoc PET (positron enhanced tomography). Autoimmune screening and serum electrophoresis were done to rule out multiple myeloma. Monitoring of the patient's blood sugars was done by the laboratory, glucometer readings, and a freestyle libre glucose monitoring system. Remission of hypoglycaemic episodes, hyperglycaemic episodes, and marked reduction of serum insulin and insulin autoantibodies in four out of six patients with diet therapy and steroids. Two patients resistant to steroids were treated with rituximab successfully. Patient 6 developed serious complications of cytomegalovirus and after rituximab, which were treated successfully. A careful history including recent infections, medications, and vaccinations provides vital clues in the evaluation. An increased awareness of IAS will prevent unnecessary and costly investigations and surgery. Although it is often self-remitting, steroids are contributory in severe cases. Immunosuppressives are used successfully in cases refractory to steroids. Continuous glucose monitoring system (CGMS), by freestyle libre glucose monitoring system, provided real-time blood sugar values, total time in hypoglycaemia, and total time in the range (TIR), which proved very valuable in managing IAS patients. Low CGMS values should be corroborated clinically and with laboratory or glucometer values.